drugset
drugset / Trial / NCT04340427

A Study of TQB3455 Tablets in Subjects With Advanced Malignancies

NCT04340427 ↗

Phase 1 Unknown 50 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a open-label, multicenter, phase I study to evaluate tolerance and pharmacokinetics of TQB3455 tablets in subjects with advanced malignancies.

Timeline

Start
2020-04-10
Primary completion
2021-06-30
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject TQB3455 Small molecule — Oral

Indications

cancer